PROMOMED Company has received a registration certificate for the drug Tirzetta® in Azerbaijan
10.11.2026
Corporate
For investors
Medicines
Industry development
Education
R&D
10.11.2026
The agreement, signed within the framework of the Kurchatov Genomic Forum, provides for conducting scientific research at unique megascience facilities, as well as using the engineering and biological infrastructure of the Kurchatov Complex of Medical Primatology.
The document was signed by Mikhail Kovalchuk, President of the Kurchatov Institute Research and Development Center, and Peter Bely, Chairman of the Board of Directors of PROMOMED.
© Photo: press service of the Kurchatov Institute Research Center
The partnership provides for the use of high-tech research infrastructure to create innovative medicines and medical technologies aimed at improving the quality and longevity of life.
Within the framework of the cooperation
, it is planned to use high-precision methods, including X-ray diffraction
analysis, which makes it possible to determine the location of an atom with an accuracy of 0.1 fractions.
"The government has invested huge amounts of money in research infrastructure. Now
It is crucial that these expensive and very complex installations are effective.
they were used, and their application was aimed at creating new technologies and
First of all, it is aimed at prolonging a high—quality and long life. Today, the key tool for creating innovative drugs is X-ray diffraction analysis, which is used at all stages: from selecting promising molecules to optimizing their properties and increasing therapeutic effectiveness."
Of particular importance in the joint work will be the use of the primatological base, which is possessed by the Kurchatov Institute Research Center. Research on higher primates allows us to test hypotheses and test prototypes on models that are as close to humans as possible. This is critically important for evaluating the safety and effectiveness of new drugs, including in the field of age-related change management.
"The agreement signed today is aimed at implementing the most important task of modern pharmaceuticals — the fundamental management of biological age and cognitive longevity. Traditional preclinical models in the research of high-tech drugs often exhaust their potential. The introduction of advanced imaging techniques, high-precision structural studies, and neurophysiological monitoring in primate research opens up a fundamentally different level of translational medicine for us. The proximity of primates to humans, combined with modern analytics, makes it possible to assess the pharmacodynamics and neuroprotective potential of molecules with unprecedented accuracy even at the preclinical stage, minimizing risks during the transition to clinical trials and bringing the creation of effective therapies for age-related diseases closer," said Petr Bely.
SIC Kurchatov Institute and PROMOMED plan to combine efforts in the development of medicinal substances, radiopharmaceuticals, in the study of genetic mechanisms and the possibilities of controlling the expression of enzymes and trace elements, as well as in the study of potential therapeutic approaches to improve cognitive functions and slow down the aging process using primatological models.
The collaboration between the Kurchatov Institute and PROMOMED is designed to accelerate the transition from scientific hypotheses to practical solutions.
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
